zurück

Dapagliflozin (new indication: chronic kidney disease)

Subject:

  • Active Substance: Dapagliflozin
  • Name: Forxiga®
  • Therapeutic area: Chronic kidney diaease
  • Pharmaceutical company: AstraZeneca GmbH

Time table:

  • Start: 01.09.2021
  • Final decision by G-BA: 17.02.2022

Final decision:

  • Patients without symptomatic chronic heart failure as a comorbidity:
    - Hint for a considerable additional benefit
  • Patients with symptomatic heart failure as a comorbidity:
    - Hint for a minor additional benefit